Business Wire

CA-NEXON-AMERICA

28.10.2021 15:02:07 CEST | Business Wire | Press release

Share
Mobile RPG KonoSuba: Fantastic Days Partners with Re:ZERO for Collaboration Event, Taking Place November 9!

Today, leading game publisher Nexon announced free-to-play mobile RPG KonoSuba: Fantastic Days will be teaming up with the fellow popular isekai anime series Re:ZERO for a limited time collaboration event from November 9 - 23.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028005593/en/

Fans can pre-register starting today here . Players will be able to earn special rewards through participating in the following events held on the page:

  • Pre-register for an Adventure!: The higher the number of cumulative pre-registers, the richer the rewards will be for all players! Players will be eligible to receive these rewards for each milestone achieved in-game from November 9 - 15.
  • Do you have what it takes to adventure with Emilia?: Fans will be able to learn more about Re:ZERO’s half-elf heroine Emilia through the online quiz.
  • Celebrate our Collaboration with Log-in Bonuses!: Players will be able to receive high-value items every day they log in while counting down for the Re:ZERO collaboration.

The KonoSuba: Fantastic Days and Re:ZERO special collaboration events include:

  • God's Blessing on Those from Re:ZERO!: Fans will be delighted to see characters from KonoSuba and Re:ZERO interact with each other in this exclusive story. Players who complete the story event will receive a four-star Emilia recruit to use in-game.
  • Re:ZERO Collaboration Recruit: In this recruit event, players have the chance to recruit Megumin and Aqua in new Re:ZERO inspired costumes and fan favorite maid Rem from Re:ZERO .
  • Battle Arena EX Boss Petelgeuse: Players will face off against Re:ZERO’s Sin Archbishop of the Witch Cult, Petelgeuse, in this all new game mode.

In addition to the Re:ZERO fun, KonoSuba: Fantastic Days will include the following major updates:

  • Main Story - Chapter 10: Players will be able to enjoy the next part of the main KonoSuba: Fantastic Days story with the addition of this chapter.
  • Trial of the Ancients: This new game mode allows players to further train their team members.
  • Battle Arena EX: This new Battle Arena will offer players exclusive and high value rewards.

KonoSuba: Fantastic Days is published by Nexon in partnership with KonoSuba publisher Kadokawa, and developed by Sumzap. ©2019 N・K/K/KMP ©Sumzap, Inc. ©NEXON All Rights Reserved. ©TN,K,Re:ZERO2P

To stay up-to-date on KonoSuba: Fantastic Days , visit the Google Play or App Store page, and be sure to follow @PlayKonoSuba on Instagram and Twitter for the latest news!

Assets : Press Assets

Social Media: Twitch / Twitter / Instagram / Discord / Facebook

About Re:ZERO -Starting Life in Another World-

Re:ZERO -Starting Life in Another World- is a famous Japanese light novel written by Tappei Nagatsuki and illustrated by Shinichirou Otsuka. The story revolves around the struggles of a recluse named Natsuki Subaru, who is suddenly summoned to another world where he utilizes his skill to rewind time upon his death. Re:ZERO is widely adopted for various content such as novels, TV animation, manga, and games.

About KonoSuba: Fantastic Days konosuba.nexon.com

Based on the popular anime series “KonoSuba: God's Blessing on this Wonderful World! ”, KonoSuba: Fantastic Days is a free-to-play character-collection RPG for iOS and Android. Featuring fan-favorite characters, including Kazuma Satou, Aqua, Megumin and Darkness, the game follows the storyline from the original novel and includes bespoke characters created exclusively for the game. Last year, the Japanese release of KonoSuba: Fantastic Days saw great success, garnering recognition from players and praise from the KonoSuba fan base.

About Nexon America Inc. https://www.nexon.com/

Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye